Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy

Pediatric Blood and Cancer

Volumn 57, Issue 6, 2011, Pages 921-929

  Meadors, Joanna L ^a   Cui, Yonghzi ^a   Chen, Qing Rong ^a   Song, Young K ^a   Khan, Javed ^a   Merlino, Glenn ^a   Tsokos, Maria ^a   Orentas, Rimas J ^a   Mackall, Crystal L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adoptive immunotherapy; Embryonal rhabdomyosarcoma; Immunotherapy; Regulatory T cells; Rhabdomyosarcoma; Tumor antigen; Tumor vaccine

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; EMBRYONAL RHABDOMYOSARCOMA VACCINE; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PC61; MUTANT PROTEIN; PROTEIN P53; SCATTER FACTOR; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG POTENCY; DRUG PULSE THERAPY; DRUG RESPONSE; EMBRYONAL RHABDOMYOSARCOMA; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL; T CELL DEPLETION; TRANSGENIC MOUSE; TUMOR CELL DESTRUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; FEMALE; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; RHABDOMYOSARCOMA; T-LYMPHOCYTES, REGULATORY;

EID: 80052686056     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23048     Document Type: Article

References (46)

1. Pappo AS, Lyden E, Breneman J, et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: An intergroup rhabdomyosarcoma study. J Clin Oncol 2001;19:213-219.
2. Cosetti M, Wexler LH, Calleja E, et al. Irinotecan for pediatric solid tumors: The Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol 2002;24:101-105.
3. Spunt SL, Smith LM, Ruymann FB, et al. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Clin Cancer Res 2004;10:6072-6079.
4. Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-A report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003;21:78-84.
5. Pappo AS, Anderson JR, Crist WM, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol 1999;17:3487-3493.
6. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572-1582.
7. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-1166.
8. Yannelli JR, Hyatt C, McConnell S, et al. Growth of tumor-infiltrating lymphocytes from human solid cancers: Summary of a 5-year experience. Int J Cancer 1996;65:413-421.
9. Dillman RO, Oldham RK, Tauer KW, et al. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: A National Biotherapy Study Group trial. J Clin Oncol 1991;9:1233-1240.
10. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283-2289.
11. Porter DL, Antin JH. Infusion of donor peripheral blood mononuclear cells to treat relapse after transplantation for chronic myelogenous leukemia. Hematol Oncol Clin North Am 1998;12:123-150.
12. Finke LH, Wentworth K, Blumenstein B, et al. Lessons from randomized phase III studies with active cancer immunotherapies-Outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine 2007;25:B97-B109.
13. Loren AW, Porter DL. Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation. Curr Opin Oncol 2006;18:107-114.
14. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival-A report from the Children's Oncology Group. J Clin Oncol 2008;26:633-638.
15. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14:1264-1270.
16. Weigel BJ, Rodeberg DA, Krieg AM, et al. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 2003;9:3105-3114.
17. Sharp R, Recio JA, Jhappan C, et al. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med 2002;8:1276-1280.
18. Tamayo P, Scanfeld D, Ebert BL, et al. Metagene projection for cross-platform, cross-species characterization of global transcriptional states. Proc Natl Acad Sci USA 2007;104:5959-5964.
19. Henderson SR, Guiliano D, Presneau N, et al. A molecular map of mesenchymal tumors. Genome Biol 2005;6:R76.
20. Neale G, Su X, Morton CL, et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 2008;14:4572-4583.
21. Chen QR, Vansant G, Oades K, et al. Diagnosis of the small round blue cell tumors using multiplex polymerase chain reaction. J Mol Diagn 2007;9:80-88.
22. Romualdi C, De Pitta C, Tombolan L, et al. Defining the gene expression signature of rhabdomyosarcoma by meta-analysis. BMC Genomics 2006;7:287.
23. Johnson BD, Jing W, Orentas RJ. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. J Immunother 2007;30:203-214.
24. Fry TJ, Shand JL, Milliron M, et al. Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to other approaches. Cancer Immunol Immunother 2009;58:1257-1264.
25. Thistlethwaite FC, Elkord E, Griffiths RW, et al. Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. Cancer Immunol Immunother 2008;57:623-634.
26. Sportes C, Hakim FT, Memon SA, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008;205:1701-1714.
27. Lacelle MG, Jensen SM, Fox BA. Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. Clin Cancer Res 2009;15:6881-6890.
28. Cui Y, Zhang H, Meadors J, et al. Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. Blood 2009;114:3831-3840.
29. Rousseau RF, Haight AE, Hirschmann-Jax C, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003;101:1718-1726.
30. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001;61:8513-8519.
31. De Angulo G, Hernandez M, Morales-Arias J, et al. Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. J Pediatr Hematol Oncol 2007;29:48-52.
32. DuBois SG, Elterman K, Grier HE. Early lymphocyte recovery in Ewing sarcoma. J Pediatr Hematol Oncol 2007;29:351-352.
33. Siddiqui M, Ristow K, Markovic SN, et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 2006;134:596-601.
34. Finkelstein SE, Heimann DM, Klebanoff CA, et al. Bedside to bench and back again: How animal models are guiding the development of new immunotherapies for cancer. J Leukoc Biol 2004;76:333-337.
35. Overwijk WW, Tsung A, Irvine KR, et al. gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998;188:277-286.
36. Orentas RJ, Kohler ME, Johnson BD. Suppression of anti-cancer immunity by regulatory T cells: Back to the future. Semin Cancer Biol 2006;16:137-149.
37. Merchant MS, Melchionda F, Sinha M, et al. Immune reconstitution prevents metastatic recurrence of murine osteosarcoma. Cancer Immunol Immunother 2007;56:1037-1046.
38. Yu Y, Khan J, Khanna C, et al. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 2004;10:175-181.
39. Nishijo K, Chen QR, Zhang L, et al. Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Res 2009;69:2902-2911.
40. Grass B, Wachtel M, Behnke S, et al. Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and AP2beta as biomarkers for rhabdomyosarcoma diagnostics. Histopathology 2009;54:873-879.
41. Johnson BD, Yan X, Schauer DW, et al. Dual expression of CD80 and CD86 produces a tumor vaccine superior to single expression of either molecule. Cell Immunol 2003;222:15-26.
42. Mackall CL, Fleisher TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994;84:2221-2228.
43. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007;117:1137-1146.
44. Prasad SJ, Farrand KJ, Matthews SA, et al. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J Immunol 2005;174:90-98.
45. Goforth R, Salem AK, Zhu X, et al. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma. Cancer Immunol Immunother 2009;58:517-530.
46. Delluc S, Hachem P, Rusakiewicz S, et al. Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response. Cancer Immunol Immunother 2009;58:1669-1677.